MYBL2 and colorectal carcinoma: Here, we showed that the combination of MYBL2 knockdown with MK-1775, a clinical phase II trial WEE1-inhibitory drug, synergistically inhibited CRC proliferation in vitro and xenograft growth in vivo with a low systemic toxicity (Fig. 5A-5I).